title: Requirements for a lead compound to become a clinical candidate.
abstract: A drug candidate suitable for clinical testing is expected to bind selectively to the receptor site on the target, to elicit the desired functional response of the target molecule, and to have adequate bioavailability and biodistribution to elicit the desired responses in animals and humans; it must also pass formal toxicity evaluation in animals. The path from lead to clinical drug candidate represents the most idiosyncratic segment of drug discovery and development. Each program is unique and setbacks are common, making it difficult to predict accurately the duration or costs of this segment. Because of incidents of unpredicted human toxicity seen in recent years, the regulatory agencies and public demands for safety of new drug candidates have become very strict, and safety issues are dominant when identifying a clinical drug candidate.
authors.affiliation: Avid Radiopharmaceuticals, Inc, Market Street, Philadelphia, PA 19104, USA. hefti@avidrp.com
authors.forename: Franz F
authors.initials: FF
authors.lastname: Hefti
mesh_terms: D000818:Animals; D001682:Biological Availability; D015195:Drug Design; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000191:economics / Q000379:methods; D004345:Drug Industry / Q000191:economics / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism*; D010599:Pharmacokinetics; D014018:Tissue Distribution
chemical_list: D004364:Pharmaceutical Preparations